论文部分内容阅读
目的 观察急性髓性白血病患者P170 与CD3 4 抗原表达及临床意义。方法 用流式细胞仪测 30例初治急性髓性白血病患者P170 与CD3 4 抗原的表达。结果 P170 总表达率 36 6 7%,P170 阳性的患者临床耐药率较阴性者高 (P <0 0 1)。CD3 4 表达者耐药率也较CD3 4 阴性者高 (P <0 0 1)。结论 P170 和CD3 4 表达是初治急性髓性白血病患者预后的重要指标之一。
Objective To observe the expression of P170 and CD3 4 antigen in patients with acute myeloid leukemia and its clinical significance. Methods Flow cytometry was used to detect the expression of P170 and CD3 4 in 30 newly diagnosed acute myeloid leukemia patients. Results The overall expression rate of P170 was 36 6 7%, and the clinical resistance rate of P170-positive patients was higher than that of negative ones (P <0.01). The drug resistance rate of CD3 4 expression was also higher than that of CD3 4 negative (P <0.01). Conclusions The expression of P170 and CD34 is one of the important prognostic indicators in patients with newly diagnosed acute myeloid leukemia.